Tweetovi

Blokirali ste korisnika/cu @MerrimackPharma

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @MerrimackPharma

  1. 8. lis 2018.

    We are taking a systematic approach to our preclinical development work. Learn more about our pipeline here:

    Poništi
  2. 5. lis 2018.

    Our pipeline is shaped by understanding cancer pathways, treatments designed with pharmacological properties to match disease need, and clinical strategies with clear rationale.

    Poništi
  3. 3. lis 2018.

    October is Month. At Merrimack, we stand with everyone who has been affected by this disease and we will continue to work to develop new treatments.

    Poništi
  4. 29. ruj 2018.

    At Merrimack, innovation is at our core. Want to help us answer the tough questions? Explore our open positions and join our team today:

    Poništi
  5. 25. ruj 2018.

    Meet Daryl Drummond, Ph.D., our Head of Research. Daryl is a principal inventor for many of our nanotechnology-based candidates.

    Poništi
  6. 20. ruj 2018.

    Today we announced the receipt of a $5 million milestone payment from Shire. Read more in the full release:

    Poništi
  7. 20. ruj 2018.

    Our vision is to see a world where all cancer patients and their families can live fulfilling lives.

    Poništi
  8. 18. ruj 2018.

    In case you missed our paper in , we recently developed a multi-scale computational model that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate. Read more here:

    Poništi
  9. 6. ruj 2018.

    Today we announced the completion of enrollment in our randomized Phase 2 clinical trial evaluating our lead investigational drug candidate, MM-121, in patients with heregulin positive non-small cell lung cancer. See the full release:

    Poništi
  10. 5. ruj 2018.

    This week we will be attending Baird's annual Global Health Conference. Tune in to the webcast on September 6 at 8:25 a.m.:

    Poništi
  11. 23. kol 2018.

    Innovation doesn't happen alone. Learn more about collaborating with us:

    Poništi
  12. 20. kol 2018.

    Innovation is at our core and we've built our culture on cooperation and collaboration. Learn more about our team and explore open career opportunities:

    Poništi
  13. 16. kol 2018.

    A cornerstone of our development strategy is to establish efficacy through clinical studies in biomarker-enriched patient populations. Learn more about our ongoing studies:Ê

    Poništi
  14. 13. kol 2018.

    We're developing a new generation of treatments for through a focused pipeline of precise, targeted therapies. Discover more:

    Poništi
  15. 7. kol 2018.

    Our team cares deeply about our mission and is driven by a desire to improve the lives of patients.

    Poništi
  16. 2. kol 2018.

    Check out our paper in exploring a multi-scale computational model we developed that quantitatively links chemotherapy-induced DNA damage response signaling to cell fate.

    Poništi
  17. 30. srp 2018.

    Our programs are backed by our systems biology expertise and a clear clinical rationale. Explore our published research and presentations:

    Poništi
  18. proslijedio/la je Tweet
    24. srp 2018.

    Computational modeling predicts how cancer cells respond to combinations of and inhibitors

    Poništi
  19. 25. srp 2018.

    Check out our paper published yesterday exploring a computational model that predicts the effects of combining chemotherapy with DNA repair inhibitors:

    Poništi
  20. 24. srp 2018.

    Our pipeline is shaped by a clear understanding of cancer pathways (systems biology). Learn more:

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·